Synektik misses market forecasts in Q4 after KPO-linked sales slowdown
Synektik reported weaker fourth-quarter results for 2025/26, with EBITDA and revenue both below analyst consensus. Management expects da Vinci system sales to hold at least flat in the current financial year.

In brief
- Synektik's fourth-quarter 2025/26 EBITDA of 40.5 mln zł and revenue of 165.3 mln zł fell short of analyst consensus.
- Management expects da Vinci system sales to stay at least flat year on year in 2026/27.
- The company says the weak quarter was transitional and that non-KPO funding sources are available.
Results below market expectations
Synektik's EBITDA in the fourth quarter of 2025/26 came to 40.5 mln zł, compared with a PAP Biznes consensus of 47 mln zł (Synektik poniżej oczekiwań rynku. Zysk i przychody rozminęły się z prognozami – bankier.pl). Revenue for the period reached 165.3 mln zł, against expectations of 185.1 mln zł. The distributor of medical equipment posted a decline in results for the quarter, and the figures came in clearly under analysts' forecasts (Po KPO wyniki Synektika w dół. Są niższe od oczekiwań – Puls Biznesu).
Outlook for 2026/27
Deputy chief executive Dariusz Korecki said the company plans for sales of da Vinci robotic systems to remain at least at the level of the previous year in the 2026/27 financial year (Synektik zakłada w 2026/27 utrzymanie rdr poziomu sprzedaży da Vinci; IV kw. nie reprezentuje potencjału grupy – pap.pl). He described the fourth quarter as a transitional period that does not reflect the group's potential. He also said the company expects the number of installed robotic systems to grow, and that funding sources other than KPO are available to hospitals on the market.
Link to KPO funding
The weaker quarter follows the end of demand supported by the KPO programme, the national recovery plan financing that had boosted purchases of medical equipment. Management's comments suggest the company is looking to replace that financing with other sources for its customers.
Key figures
- EBITDA, Q4 2025/26: 40.5 mln zł (consensus 47 mln zł)
- Revenue, Q4 2025/26: 165.3 mln zł (consensus 185.1 mln zł)
Sources
- #Synektik
- #DaVinci
- #KPO
- #EBITDA
- #MedicalEquipment
- #Q4Results
Story graph
Connected stories
Synektik misses market forecasts in Q4 after KPO-linked sales slowdown
Synektik reported weaker fourth-quarter results for 2025/26, with EBITDA and revenue both below analyst consensus. Management expects da Vinci system sales to…
